成人中重度银屑病非生物系统性治疗的持续性与有效性:一项系统综述
该系统综述检索2007年1月1日至2017年11月1日数据库,纳入8项观察性研究共4624例成人中重度银屑病患者,评估阿维A、环孢素、富马酸酯和甲氨蝶呤的持续性与有效性。因结局定义和分析方法不一致,无法进行Meta分析;一项前瞻性多中心研究报道1年药物存活概率环孢素23%、阿维A42%、甲氨蝶呤50%。
要点
- 纳入8项观察性研究共4624例患者,因定义与方法不一致未行Meta分析。
- 一项前瞻性多中心研究1年药物存活概率:环孢素23%、阿维A42%、甲氨蝶呤50%。
- 随访12个月时三项研究报告达到PASI≥75%改善的比例分别为富马酸酯76%、甲氨蝶呤53%和59%。
核心结论
- 因方法学不一致,过去十年真实临床实践中阿维A、环孢素、富马酸酯和甲氨蝶呤的比较性持续性与有效性无法得到良好描述。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、Cochrane图书馆和PubMed从2007年1月1日至2017年11月1日的观察性研究。
- 纳入标准为涉及至少100例成人中重度银屑病患者、治疗暴露≥3个月、报告持续性或有效性的研究。
- 共识别411项研究,最终纳入8项涉及4624例银屑病患者的研究。
- 本综述在PROSPERO注册,注册号为CRD42018099771。
主要发现
- 持续性和有效性结局的定义与分析方法存在差异,导致无法进行Meta分析。
- 一项前瞻性多中心研究报告1年药物存活概率分别为环孢素23%、阿维A42%、甲氨蝶呤50%。
- 阿维A和环孢素的有效性结局均未报告。
- 富马酸酯和甲氨蝶呤的持续性与有效性特征更明确,但平均停药时间富马酸酯为28至50个月,甲氨蝶呤为7.7至22.3个月。
- 随访12个月时,三项研究报告达到PASI≥75%改善的患者比例分别为富马酸酯76%、甲氨蝶呤53%和甲氨蝶呤59%,一项研究报告76%的富马酸酯暴露患者达到PGA明显改善或清除。
局限性
- 持续性和有效性结局的定义与分析方法存在差异,导致无法进行Meta分析。
- 阿维A和环孢素的有效性结局均未报告。
- 因方法学不一致,过去十年真实临床实践中四种药物的比较性持续性与有效性无法得到良好描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The persistence and effectiveness of systemic therapies for moderate-to-severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and effectiveness of acitretin, ciclosporin, fumaric acid esters (FAE) and methotrexate, involving at least 100 adult patients with moderate-to-severe psoriasis, exposed to therapy for ≥ 3 months. METHODS: MEDLINE, Embase, the Cochrane Library and PubMed were searched from 1 January 2007 to 1 November 2017 for observational studies reporting on persistence (therapy duration or the proportion of patients discontinuing therapy during follow-up) or effectiveness [improvements in Psoriasis Area and Severity Index (PASI) or Physician's Global Assessment (PGA)]. This review was registered with PROSPERO, number CRD42018099771. RESULTS: Of 411 identified studies, eight involving 4624 patients with psoriasis were included. Variations in the definitions and analyses of persistence and effectiveness outcomes prevented a meta-analysis from being conducted. One prospective multicentre study reported drug survival probabilities of 23% (ciclosporin), 42% (acitretin) and 50% (methotrexate) at 1 year. Effectiveness outcomes were not reported for either acitretin or ciclosporin. The persistence and effectiveness of FAE and methotrexate were better characterized, but mean discontinuation times ranged from 28 to 50 months for FAE and 7·7 to 22·3 months for methotrexate. At 12 months of follow-up, three studies reported that 76% (FAE), 53% (methotrexate) and 59% (methotrexate) of patients achieved ≥ 75% reduction in PASI, and one reported that 76% of FAE-exposed patients achieved a markedly improved or clear PGA. CONCLUSIONS: The comparative persistence and effectiveness of acitretin, ciclosporin, FAE and methotrexate in real-world clinical practice in the past decade cannot be well described due to the inconsistency of the methods used.
引用
- Mason KJ, Williams S, Yiu ZZN, et al. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. Br J Dermatol. 2019. PMID: 30628069. doi:10.1111/bjd.17625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。